Shots:

• Sorrento has filed an IND for STI-1499 in patients hospitalized with COVID-19. In preclinical studies- STI-1499 has demonstrated 100% neutralizing effect (in vitro) against the highly contagious D614G mutant strain at a low dose
• Additionally- animal model data confirms the neutralizing profile and high potency of Ab- expected effective dose in human to be at least 5 times lower than current known Abs being assessed in other active trials
• Sorrento has initiated cGMP manufacturing to produce 50-000 doses- expected to be available by the end of 2020- in anticipation of a potential EUA

­ Ref: Sorrento | Image: Blogger